We are pleased to add a new feature on Novum’s website. With a nod to our name, which translates from Latin as “new thing”, we want to share with you our energy and excitement as we embark on some bold new things. Novum Novas—occasional news and views from us about our work and our industry—will be shared here to keep our stakeholders informed and engaged.
In late January of this year, we announced our merger with Lambda Therapeutic Research, another leading CRO. Senior leadership from both Novum and Lambda had gotten to know each other over many years in the industry together. That familiarity, which built mutual respect and a common set of values, created the spark to join together and create more value for our clients.
This was a merger driven purely by strategic vision. The two companies saw a large opportunity for our clients by combining our reach, capabilities, and deep experience. Just as Novum was seeking to expand its footprint to a more global scale, leveraging its four decades of experience into new markets, Lambda was looking to establish a presence in the United States along with its holdings in India, Europe, and Canada. With aligned goals, the union was a perfect fit.
Each party has unique areas of expertise that complement the other. For Novum clients, we can immediately offer you additional new services that we keep in the family, and thereby we can be more competitive and seamless with our offerings.
You will not see a lot of change at Novum itself. Our “small company values” will be as important to us going forward as they were yesterday, with a hands-on approach from the senior team to client needs, and the strong desire to keep things simple and transparent in handling your most challenging projects.
Novum is going to remain in name, in leadership, in know-how and SOP’s, but we are eager to learn from our new partner’s experience, and work closely with them to provide a great client experience.
Look for these new service offerings that Novum can provide, leveraging the extensive reach of Lambda:
- Early phase clinical conduct in the US or Toronto, along with full-service bioanalytical capabilities. Lambda’s BA facilities in Canada and India have over 1000 validated methods and are focused strategically on supporting large molecule work.
- Novum and Lambda both have significant late phase experience. Together, we can manage global trials that span many new indications and most regions of the globe under one project.
- Lambda provides new add-on services to Novum’s core capabilities including a well-established pharmacovigilance unit based in London, and a medical imaging division.
We want to have direct discussions with all of our clients about our novas. For the many of you we’ve already spoken with, I appreciate so much your encouragement and support!
Christopher H. Chamberlain
Chief Executive Officer
Novum Pharmaceutical Research Services